# Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention

> **NCT03870438** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 1506 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** Lamivudine Oral Solution

## Key facts

- **NCT ID:** NCT03870438
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-14
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-10-31
- **Target enrollment:** 1506 (ACTUAL)
- **Last updated:** 2022-12-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03870438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03870438, "Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03870438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*